Daisuke kobayashi (22 résultats)

Paperback. Etat : New.

Etat : New.

Etat : As New. Unread book in perfect condition.

Paperback. Etat : New. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).…

Etat : New.

Etat : New. 1st edition NO-PA16APR2015-KAP.

Etat : New.

Paperback. Etat : Brand New. 75 pages. 8.94x5.98x0.24 inches. In Stock.

Etat : As New. Unread book in perfect condition.

Tankobon Hardcover. Etat : Brand New. 7.44x5.28x0.63 inches. In Stock.

Tankobon Hardcover. Etat : Brand New. Japanese language. 7.32x5.12x0.71 inches. In Stock.

Kartoniert / Broschiert. Etat : New. Inhaltsverzeichnis1.Structural biology and mechanism of activation of EGFR 2. EGFR-associated oncogenesis 3. Tyrosine kinase inhibitors (TKIs) as targeted treatment for EGFR-mutant NSCLC 4. EGFR-TKIs as adjuvant or neoadjuvant therapy.

Tankobon Hardcover. Etat : Brand New. Japanese language. 8.66x6.26x1.10 inches. In Stock.

Paperback. Etat : New. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).…

Etat : Fine. The book is in fine condition.

Etat : Fine. The book is in fine condition.

Etat : Fine. The book is in fine condition.

Paperback. Etat : New.

Etat : New. Print on Demand.

Etat : New. This book, published by KADOKAWA, provides asset strategies for navigating inflation and identifying opportunities for growing wealth while avoiding losses in the year 2035. Daisuke Kobayashi offers insights into financial planning and investment to survive economic challenges. Note: The text is entirely in Japanese. Brand New Japanese Edition. Ships worldwide from Japan via Japan Post. Expedited shipping via FedEx available.…

Etat : New. PRINT ON DEMAND.

Etat : New.